201 related articles for article (PubMed ID: 34547219)
1. Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful
Shinozaki S; Osawa H; Hayashi Y; Miura Y; Yano T; Lefor AK; Yamamoto H
Scand J Gastroenterol; 2022 Jan; 57(1):16-21. PubMed ID: 34547219
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
[TBL] [Abstract][Full Text] [Related]
3. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease.
Qian B; Ma S; Shang L; Qian J; Zhang G
Helicobacter; 2011 Aug; 16(4):255-65. PubMed ID: 21762264
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.
McColl KE; Dickson A; El-Nujumi A; El-Omar E; Kelman A
Am J Gastroenterol; 2000 Jan; 95(1):101-5. PubMed ID: 10638566
[TBL] [Abstract][Full Text] [Related]
5. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?
Fallone CA; Barkun AN; Friedman G; Mayrand S; Loo V; Beech R; Best L; Joseph L
Am J Gastroenterol; 2000 Apr; 95(4):914-20. PubMed ID: 10763937
[TBL] [Abstract][Full Text] [Related]
6. [Indications and consequences of Helicobacter pylori eradication on gastroesophageal reflux disease].
Gisbert JP; Piqué JM
Med Clin (Barc); 2005 May; 124(18):697-709. PubMed ID: 15899166
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Miura Y; Lefor AK; Yamamoto H
Kaohsiung J Med Sci; 2017 Dec; 33(12):616-622. PubMed ID: 29132551
[TBL] [Abstract][Full Text] [Related]
8. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.
Laine L; Sugg J
Am J Gastroenterol; 2002 Dec; 97(12):2992-7. PubMed ID: 12492181
[TBL] [Abstract][Full Text] [Related]
9. Gastroesophageal reflux disease and the relationship with Helicobacter pylori.
Mungan Z; Pınarbaşı Şimşek B
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S61-S67. PubMed ID: 29199171
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
[TBL] [Abstract][Full Text] [Related]
11. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
Simadibrata DM; Syam AF; Lee YY
J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, open-label, controlled trial.
Rodrigues L; Faria CM; Geocze S; Chehter L
Arq Gastroenterol; 2012; 49(1):56-63. PubMed ID: 22481687
[TBL] [Abstract][Full Text] [Related]
13. [Gastroesophageal reflux disease (GERD). Barrett esophagus].
Kato M
Nihon Rinsho; 2009 Dec; 67(12):2357-65. PubMed ID: 19999125
[TBL] [Abstract][Full Text] [Related]
14. Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study.
Wada Y; Ito M; Takata S; Kitamura S; Takamura A; Tatsugami M; Imagawa S; Matsumoto Y; Tanaka S; Yoshihara M; Chayama K
Hepatogastroenterology; 2009; 56(91-92):624-8. PubMed ID: 19621668
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
16. Early development of reflux esophagitis after successful Helicobacter pylori eradication in superficial gastritis.
Huh JH; Park MS; Jeon HH
JNMA J Nepal Med Assoc; 2011; 51(184):189-91. PubMed ID: 22922899
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan fumarate for the management of acid-related diseases.
Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
[TBL] [Abstract][Full Text] [Related]
18. Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan.
Sugimoto M; Uotani T; Ichikawa H; Andoh A; Furuta T
Digestion; 2016; 93(1):24-31. PubMed ID: 26789391
[TBL] [Abstract][Full Text] [Related]
19. Effect of Helicobacter pylori eradication on reflux esophagitis and GERD symptoms after endoscopic resection of gastric neoplasm: a single-center prospective study.
Na HK; Lee JH; Park SJ; Park HJ; Kim SO; Ahn JY; Kim DH; Jung KW; Choi KD; Song HJ; Lee GH; Jung HY
BMC Gastroenterol; 2020 Apr; 20(1):123. PubMed ID: 32316932
[TBL] [Abstract][Full Text] [Related]
20. Examination on Factors Affecting Symptom Change after Drug Withdrawal in Patients with Mild Erosive Gastroesophageal Reflux Disease Undergoing Symptom-Controlled Maintenance Therapy with Acid-Secretion Inhibition Drugs.
Tanaka H; Takeuchi T; Nishida S; Hongo H; Takii M; Higashino T; Sanomura M; Miyazaki H; Hoshimoto M; Kimura T; Sakaguchi M; Abe T; Hakoda A; Sugawara N; Iwatsubo T; Kawaguchi S; Ota K; Kojima Y; Higuchi K
Digestion; 2023; 104(4):270-282. PubMed ID: 36649678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
